BioMimetic Therapeutics (BMTI) Submits Amendment to Augment Bone Graft PMA

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) has submitted to the Food and Drug Administration (FDA) an amendment to its Pre-Market Approval (PMA) application for Augment® Bone Graft for its use as an alternative to autograft in hindfoot and ankle fusion procedures. The amendment provides supplemental information requested by the FDA in a post-panel response letter announced by the Company earlier this year.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Humacyte publishes Phase 3 hemodialysis trial data in Lancet
• Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia